

Summary of status of development and availability of variant¹ influenza A(H1) candidate vaccine viruses and potency testing reagents

26 September 2019 (*last updated on 21 November 2019*)

Candidate vaccine viruses

Antigenic prototype	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Ohio/24/2017 (H1N2)v	Wild type virus			CDC, USA
	IDCDC-RG59*	Reverse genetics	CDC, USA	CDC, USA
A/Ohio/9/2015 (H1N1)v	Wild type virus			WHO CCs
	IDCDC-RG48A*	Reverse genetics	CDC, USA	CDC, USA
A/Hunan/42443/2015 (H1N1)v	Wild type virus			WHO CCs
	CNIC-1601*	Conventional reassortant	CCDC, China	CCDC, China
A/Michigan/383/2018 (H1N2)v [#]	Wild type virus			WHO CCs
	IDCDC-RG58A*	Reverse genetics	CDC, USA	CDC, USA

*These viruses are candidate vaccine viruses which have passed relevant safety testing. They can be handled under BSL-2 enhanced containment². *New CVV shown in blue font.*

Candidate vaccine viruses in preparation

Antigenic prototype	Type of virus or reassortant	Developing Institute	Status
A/Ohio/35/2017 (H1N2)v	Classical	NIBSC	Pending
A/Iowa/32/2016 (H1N2)v	Reverse genetics	CDC, USA	Pending
A/Netherlands/3315/2016 (H1N1)v	Classical	NIBSC	Pending

Institutes contact details for candidate vaccine viruses orders/information:

CCDC: whocc-china@cnic.org.cn
 CDC: dwentworth@cdc.gov (Subject: CVV request)
 NIBSC: standards@nibsc.org or enquiries@nibsc.org

¹ Joint FAO, OIE, WHO announcement of the standardization of influenza virus variants infecting humans: http://www.who.int/influenza/gisrs_laboratory/terminology_variant/en/

² <http://www.who.int/biologicals/publications/trs/areas/vaccines/influenza/Annex%205%20human%20pandemic%20influenza.pdf?ua=1>

WHO CCs: http://www.who.int/influenza/gisrs_laboratory/collaborating_centres/list/en/

For other candidate vaccine viruses and potency testing reagents, please go to <http://www.who.int/influenza/vaccines/virus/en/>

For general enquiries, please contact gisrs-whohq@who.int